Patterns of somatic mutation in human cancer genomes

Cancers arise owing to mutations in a subset of genes that confer growth advantage. The availability of the human genome sequence led us to propose that systematic resequencing of cancer genomes for mutations would lead to the discovery of many additional cancer genes. Here we report more than 1,000 somatic mutations found in 274 megabases (Mb) of DNA corresponding to the coding exons of 518 protein kinase genes in 210 diverse human cancers. There was substantial variation in the number and pattern of mutations in individual cancers reflecting different exposures, DNA repair defects and cellular origins. Most somatic mutations are likely to be ‘passengers’ that do not contribute to oncogenesis. However, there was evidence for ‘driver’ mutations contributing to the development of the cancers studied in approximately 120 genes. Systematic sequencing of cancer genomes therefore reveals the evolutionary diversity of cancers and implicates a larger repertoire of cancer genes than previously anticipated.

[1]  N. Goldman,et al.  A codon-based model of nucleotide substitution for protein-coding DNA sequences. , 1994, Molecular biology and evolution.

[2]  K. Kinzler,et al.  Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. , 1995, Science.

[3]  M. Skolnick,et al.  Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor. , 1997, Cancer research.

[4]  C. Sunkel,et al.  Human Autoantibodies Reveal Titin as a Chromosomal Protein , 1998, The Journal of cell biology.

[5]  R. Hruban,et al.  Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene. , 1998, Cancer research.

[6]  D. Chopin,et al.  Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas , 1999, Nature Genetics.

[7]  J. Avruch,et al.  Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. , 2001, Physiological reviews.

[8]  Victor E. Velculescu,et al.  Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis , 2001, Nature Genetics.

[9]  E. Birney,et al.  Cancer and genomics , 2001, Nature.

[10]  Giovanni Parmigiani,et al.  Prevalence of somatic alterations in the colorectal cancer cell genome , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[11]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[12]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[13]  A. V. D. van den Ouweland,et al.  FGFs, their receptors, and human limb malformations: clinical and molecular correlations. , 2002, American journal of medical genetics.

[14]  Richard Wooster,et al.  BRAF and RAS mutations in human lung cancer and melanoma. , 2002, Cancer research.

[15]  D. DiMaio,et al.  Definition of an Inhibitory Juxtamembrane WW-like Domain in the Platelet-derived Growth Factor β Receptor* , 2002, The Journal of Biological Chemistry.

[16]  David Sidransky,et al.  Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. , 2002, Cancer research.

[17]  B. Rannala,et al.  Likelihood models of somatic mutation and codon substitution in cancer genes. , 2003, Genetics.

[18]  P. Karran,et al.  Human mismatch repair, drug-induced DNA damage, and secondary cancer. , 2003, Biochimie.

[19]  Giovanni Parmigiani,et al.  Mutational Analysis of the Tyrosine Kinome in Colorectal Cancers , 2003, Nature Reviews Cancer.

[20]  Y. Shiloh.  ATM and related protein kinases: safeguarding genome integrity , 2003, Nature Reviews Cancer.

[21]  T. Hubbard,et al.  A census of human cancer genes , 2004, Nature Reviews Cancer.

[22]  M. Bogoyevitch,et al.  Targeting the JNK MAPK cascade for inhibition: basic science and therapeutic potential. , 2004, Biochimica et biophysica acta.

[23]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[24]  C. Sawyers,et al.  Targeted cancer therapy , 2004, Nature.

[25]  E. Birney,et al.  Reactome: a knowledgebase of biological pathways , 2004, Nucleic Acids Research.

[26]  Andrew D. Yates,et al.  Somatic mutations of the protein kinase gene family in human lung cancer. , 2005, Cancer research.

[27]  J. Ptak,et al.  Colorectal cancer: Mutations in a signalling pathway , 2005, Nature.

[28]  A. Brandes,et al.  Adjuvant chemotherapy in the treatment of high grade gliomas. , 2005, Cancer treatment reviews.

[29]  Hiroaki Kitano,et al.  The PANTHER database of protein families, subfamilies, functions and pathways , 2004, Nucleic Acids Res..

[30]  Andrew D. Yates,et al.  A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer , 2005, Nature Genetics.

[31]  H. Granzier,et al.  Titin and its associated proteins: the third myofilament system of the sarcomere. , 2005, Advances in protein chemistry.

[32]  M. Stratton,et al.  Statistical Analysis of Pathogenicity of Somatic Mutations in Cancer , 2006, Genetics.

[33]  Toshihisa Takagi,et al.  Event Ontology: A Pathway-Centric Ontology for Biological Processes , 2006, Pacific Symposium on Biocomputing.

[34]  K. Wilson,et al.  Nuclear Titin interacts with A- and B-type lamins in vitro and in vivo , 2006, Journal of Cell Science.

[35]  Richard Lugg,et al.  Sequence analysis of the protein kinase gene family in human testicular germ‐cell tumors of adolescents and adults , 2006, Genes, chromosomes & cancer.

[36]  G. Parmigiani,et al.  The Consensus Coding Sequences of Human Breast and Colorectal Cancers , 2006, Science.

[37]  Nazneen Rahman,et al.  ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles , 2006, Nature Genetics.

[38]  Tracy T Batchelor,et al.  A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. , 2006, Cancer research.